Unweighted Population

Weighted Population*

DRV/c/FTC/TAF Cohort (n=122)

BIC/FTC/TAF
Cohort (n=827)

Standardized Difference

DRV/c/FTC/TAF Cohort
(Weighted n=452)

BIC/FTC/TAF
Cohort (Weighted n=497)

Standardized Difference

Variables Included in the PS Model*

Age (years), Mean ± SD [median]

52.3 ± 10.5 [53.5]

52.2 ± 12.1 [54.0]

1.4%

53.1 ± 11.2 [54.0]

52.2 ± 12.0 [54.0]

8.0%

Female, n (%)

32 (26.2)

234 (28.3)

4.6%

136 (30.0)

140 (28.2)

4.0%

Race, n (%)

White

41 (33.6)

299 (36.2)

5.3%

144 (31.9)

178 (35.8)

8.2%

Black/African American

36 (29.5)

221 (26.7)

6.2%

138 (30.6)

135 (27.2)

7.7%

Hispanic

13 (10.7)

66 (8.0)

9.2%

40 (9.0)

41 (8.3)

2.5%

Other

1 (0.8)

15 (1.8)

8.7%

7 (1.5)

9 (1.8)

1.9%

Unknown

31 (25.4)

226 (27.3)

4.4%

122 (27.0)

134 (27.0)

0.1%

US Geographic Region, n (%)

South

73 (59.8)

542 (65.5)

11.8%

292 (64.7)

323 (65.1)

0.8%

West

24 (19.7)

81 (9.8)

28.1%

63 (13.9)

54 (10.8)

9.6%

Northeast

18 (14.8)

96 (11.6)

9.3%

60 (13.3)

60 (12.0)

4.0%

Midwest

7 (5.7)

107 (12.9)

24.9%

36 (8.1)

60 (12.1)

13.3%

Unknown

0 (0.0)

1 (0.1)

4.9%

0 (0.0)

1 (0.1)

4.8%

Insurance Plan/Payer Type, n (%)

Medicare

38 (31.1)

218 (26.4)

10.6%

128 (28.3)

134 (26.9)

3.3%

Medicaid

37 (30.3)

143 (17.3)

31.0%

92 (20.4)

93 (18.8)

4.2%

Commercial Plans

35 (28.7)

384 (46.4)

37.3%

169 (37.4)

221 (44.4)

14.3%

Assistance Programs

12 (9.8)

81 (9.8)

0.1%

63 (13.9)

49 (9.9)

12.3%

Cash

0 (0.0)

1 (0.1)

4.9%

0 (0.0)

1 (0.1)

4.8%

Year of Index Date, n (%)

2018

48 (39.3)

406 (49.1)

19.7%

195 (43.2)

238 (48.0)

9.5%

2019

74 (60.7)

421 (50.9)

19.7%

257 (56.8)

259 (52.0)

9.5%

Comorbidities, n (%)

Substance-related and Addictive Disorders

26 (21.3)

106 (12.8)

22.7%

72 (16.0)

68 (13.7)

6.4%

Hypertension

42 (34.4)

293 (35.4)

2.1%

155 (34.3)

176 (35.4)

2.2%

Type 2 Diabetes Mellitus

15 (12.3)

134 (16.2)

11.2%

70 (15.6)

79 (15.9)

0.8%

Obesity

12 (9.8)

142 (17.2)

21.6%

73 (16.0)

81 (16.4)

0.9%

Quan-CCI, Mean ± SD [median]

5.3 ± 2.7 [6.0]

4.8 ± 3.0 [6.0]

16.6%

5.0 ± 2.9 [6.0]

4.9 ± 3.0 [6.0]

5.2%

Patients with a BMI Measurement, n (%)

122 (100.0)

817 (98.8)

15.6%

452 (100.0)

491 (98.7)

16.0%

BMI (kg/m²), Mean ± SD [median]

28.5 ± 7.1 [27.6]

29.5 ± 6.7 [28.4]

13.9%

28.8 ± 7.2 [28.2]

29.4 ± 6.7 [28.3]

9.6%

BMI Categories (kg/m²), n (%)

<25

38 (31.1)

234 (28.6)

5.5%

137 (30.3)

141 (28.7)

3.5%

≥25 to <30

44 (36.1)

247 (30.2)

12.4%

143 (31.5)

152 (30.9)

1.4%

≥30 to <35

17 (13.9)

182 (22.3)

21.8%

86 (19.0)

105 (21.4)

6.0%

≥35

23 (18.9)

154 (18.8)

0.0%

86 (19.1)

93 (19.0)

0.4%

Variables Not Included in the PS Model

Comorbidities, n (%)

Anxiety Disorders

19 (15.6)

114 (13.8)

5.1%

70 (15.5)

70 (14.0)

4.2%

Depression

28 (23.0)

129 (15.6)

18.7%

98 (21.6)

79 (15.9)

14.7%

Chronic Pulmonary Disease

21 (17.2)

131 (15.8)

3.7%

74 (16.4)

82 (16.4)

0.1%

Drug Abuse

12 (9.8)

47 (5.7)

15.6%

31 (6.9)

31 (6.2)

2.7%

Pre-diabetes

5 (4.1)

32 (3.9)

1.2%

22 (5.0)

19 (3.8)

5.6%

Psychoses

8 (6.6)

50 (6.0)

2.1%

23 (5.2)

32 (6.4)

5.4%

Quan-CCI (excluding HIV-1 symptoms), Mean
± SD [median]

0.5 ± 0.9 [0.0]

0.6 ± 0.9 [0.0]

10.7%

0.5 ± 0.9 [0.0]

0.6 ± 0.9 [0.0]

13.3%

Patients with a Weight Measurement, n (%)

121 (99.2)

822 (99.4)

2.6%

449 (99.3)

494 (99.4)

0.3%

Weight (kg), Mean ± SD [median]

87.2 ± 22.8 [85.3]

88.3 ± 21.5 [85.3]

5.1%

87.1 ± 22.9 [88.0]

88.2 ± 21.5 [85.3]

5.0%

Patients with an Absolute CD4 Cell Count Measurement, n (%)

25 (20.5)

241 (29.1)

20.1%

96 (21.2)

145 (29.2)

18.6%

CD4 Cell Count (cells/µL), Mean ± SD [median]

639.3 ± 362.9
[585.0]

745.9 ± 366.4
[684.0]

29.2%

714.5 ± 405.4
[615.0]

747.0 ± 367.1
[684.0]

8.4%

Patients with an Absolute CD8 Cell Count Measurement, n (%)

13 (10.7)

127 (15.4)

14.0%

45 (10.1)

76 (15.2)

15.6%

CD8 Cell Count (cells/µL), Mean ± SD [median]

933.7 ± 555.6
[790.0]

901.5 ± 417.7
[816.0]

6.6%

896.0 ± 557.3
[764.0]

904.8 ± 419.1
[818.0]

1.8%

Patients with a HIV-1 Viral Load
Measurement, n (%)

51 (41.8)

291 (35.2)

13.6%

183 (40.5)

177 (35.6)

10.0%

HIV-1 Viral Load (copies/mL), Mean ± SD [median]

13.4 ± 12.6 [20.0]

4180.7 ± 29 430.1
[20.0]

20.0%

14.5 ± 13.5 [20.0]

4021.7 ± 28 893.7
[20.0]

19.6%

Patients with HIV- 1 Disease Onset
Information in EMR Data, n (%)

58 (47.5)

334 (40.4)

14.5%

242 (53.6)

200 (40.3)

27.0%

Time (in months) Between HIV-1 Disease Onset and Index Date, Mean ± SD [median]

147.3 ± 131.4
[87.4]

118.3 ± 224.0
[71.7]

15.8%

129.1 ± 123.4
[85.8]

118.8 ± 222.4
[72.1]

5.7%

Patients who Switched from a Previous ART to the Index Regimen During the Last 45 Days, n (%)

92 (75.4)

537 (64.9)

23.1%

332 (73.5)

323 (65.0)

18.5%

Patients who Switched from a PI

73 (59.8)

83 (10.0)

122.5%

258 (57.1)

51 (10.2)

114.3%

DRV-based

67 (54.9)

39 (4.7)

131.3%

244 (54.0)

24 (4.9)

128.1%

Other PI-based

6 (4.9)

44 (5.3)

1.8%

14 (3.0)

27 (5.3)

11.5%

Patients who Switched from an INSTI

26 (21.3)

297 (35.9)

32.7%

101 (22.4)

179 (36.1)

30.4%

Dolutegravir-based

16 (13.1)

108 (13.1)

0.2%

68 (15.1)

66 (13.3)

5.3%

Elvitegravir-based

4 (3.3)

161 (19.5)

52.7%

13 (2.8)

96 (19.3)

54.8%

Raltegravir-based

5 (4.1)

28 (3.4)

3.8%

19 (4.1)

17 (3.5)

3.5%

Bictegravir-based

1 (0.8)

0 (0.0)

12.9%

2 (0.4)

0 (0.0)

8.9%

Patients who Switched from an NNRTI

2 (1.6)

165 (20.0)

61.8%

7 (1.5)

99 (19.9)

62.1%

NRTIs Used +/- 14 days from the Most Recent Switch, Among Switchers n (%)

FTC/TAF

65 (70.7)

267 (49.7)

43.8%

216 (65.1)

162 (50.2)

30.5%

FTC/TDF

10 (10.9)

171 (31.8)

52.9%

43 (13.0)

101 (31.3)

45.3%

Abacavir/lamivudine

7 (7.6)

54 (10.1)

8.6%

36 (10.8)

33 (10.2)

2.0%